Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

B

Barts & The London NHS Trust

Other

0

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

0

Indications↗

Distinct diseases across all programs

43

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Key Events

Oct 3, 2026TrialSingle Centre Prospective Study to Obtain Data to Train an Algorithm for Prediction of Outcome in Transcatheter Aortic Valve Implantation (TAVI)

Sep 23, 2026TrialStereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia

Sep 23, 2026TrialEVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients

Sep 23, 2026TrialObjective Randomised Blinded Investigation of Cardioversion Versus Ablation for Persistent Atrial Fibrillation (ORBICA-AF)

Sep 22, 2026TrialCatheter Ablation Versus Medical Treatment of AF in Heart Failure

Sep 18, 2026FDAPotassium — DICLOFENAC POTASSIUM

Sep 9, 2026TrialCerebral Protection in Aortic Arch Surgery

Sep 9, 2026TrialThe Use of Continuous Electroencephalographic (EEG) Monitoring for Cases of Refractory Status Epilepticus: Does it Affect the Final Patient Outcome

4 more events

Sep 9, 2026TrialA Prospective Single Arm Pilot Study to Investigate the Dynamic Brain and Multifidus Muscle Imaging in Response to Multifidus Stimulation in Patients With Low Back Pain Undergoing Reactiv8 Implant

Jul 17, 2026TrialClinical Phenotypes, Risk Factors, & Determinants of Outcome in Functional Mitral and Tricuspid Valve Regurgitation

Jul 17, 2026FDAPotassium — AUGMENTIN '125', AUGMENTIN '250'

Jun 26, 2026TrialConvergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Regulatory

Regulatory Timeline

202514 events

FDADec 16

Potassium — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Application ANDA091617

FDANov 20

Potassium — POTASSIUM CHLORIDE

Application ANDA216536

FDANov 12

Potassium — POKONZA, POTASSIUM CHLORIDE

Application NDA208019

FDANov 5

Potassium — LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

Application NDA016679

FDANov 5

Potassium — POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

Application NDA019367

FDASep 30

Potassium — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Application ANDA091629

FDASep 10

Potassium — POTASSIUM CHLORIDE

Application ANDA218733

FDASep 9

Potassium — LOSARTAN POTASSIUM

Application ANDA217396

FDAAug 29

Potassium — DICLOFENAC POTASSIUM

Application ANDA217010

FDAAug 6

Potassium — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Application ANDA204832

FDAJul 10

Potassium — DICLOFENAC POTASSIUM

Application ANDA210078

FDAJul 10

Potassium — DICLOFENAC POTASSIUM

Application ANDA210078

FDAJul 10

Potassium — DICLOFENAC POTASSIUM

Application ANDA210078

FDAJul 10

Potassium — DICLOFENAC POTASSIUM

Application ANDA210078

20266 events

FDASep 18

Potassium — DICLOFENAC POTASSIUM

Application ANDA075229

FDAJul 17

Potassium — AUGMENTIN '125', AUGMENTIN '250'

Application NDA050575

FDAJun 12

Potassium — POKONZA, POTASSIUM CHLORIDE

Application NDA206814

FDAMar 12

Potassium — POTASSIUM PHOSPHATES

Application ANDA220373

FDAFeb 17

Potassium — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Application ANDA202289

FDAFeb 15

Potassium — AMOXICILLIN AND CLAVULANATE POTASSIUM

Application ANDA201090

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)